Surgical Outcomes of Ahmed Glaucoma Valve Implantation with Postoperative Use of Prednisolone Acetate versus Difluprednate

Kao, Brandon W.; Fong, Christopher W; Yu, Yinxi; Ying, Gui‐Shuang; Gedde, Steve J.; Han, Ying

doi:10.1016/j.ogla.2022.03.003

Cited by 7 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We hypothesize that with the better postoperative inflammatory control, difluprednate may not only prevent ECL but also have the added benefit of less fibrous encapsulation of the GDD, leading to better IOP control. While a recent retrospective study found that postoperative treatment with 0.05% difluprednate after AGV resulted in a similar IOP when difluprednate was used in less frequency than prednisolone 1%, 24 a future RCT to evaluate the effect of difluprednate vs prednisolone acetate in GDD is still needed.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Survey of the American Glaucoma Society Membership on Current Glaucoma Drainage Device Placement and Postoperative Corticosteroid Use

Yonamine¹,

Ton²,

Rose‐Nussbaumer³

et al. 2022

OPTH

Self Cite

View full text Add to dashboard Cite

Purpose To assess practice patterns and opinions of glaucoma specialists regarding glaucoma drainage device tube shunt placement and post-operative anti-inflammatory medication use. We also assess the perceived need for a randomized control trial to compare them. Patients and Methods An online survey was distributed to a group of glaucoma specialists from the American Glaucoma Society via the American Glaucoma Society forum from April to August 2021. Results One hundred and twenty-eight responses were included. Ninety percent placed tubes in the anterior chamber. Sixty-one percent reported that evidence suggested the superiority of sulcus tube placement over the anterior chamber, whereas 34% reported there was not enough evidence to suggest superiority of either in preventing endothelial cell loss. Comparing these techniques for intraocular pressure control, 49% reported evidence suggested sulcus tube placement superiority whereas 46% reported there was not enough evidence. Over 40% of respondents reported that they were either unfamiliar with literature or that there was not enough evidence to support the superiority of difluprednate 0.05% over prednisolone 1% for post-operative use in preventing endothelial cell loss and for intraocular pressure control. Ninety percent and 81% of respondents respectively would benefit from randomized control trials comparing outcomes of anterior chamber vs sulcus tube placement and post-operative corticosteroid usage. Conclusion Most glaucoma specialists surveyed place glaucoma drainage device tube in the anterior chamber over the sulcus. A randomized control trial to determine optimal tube placement and post-operative anti-inflammatory medication use for preventing endothelial cell loss would change current glaucoma drainage device practice patterns.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Clinical Ophthalmology 2022:16 2308 postoperative treatment with 0.05% difluprednate after AGV resulted in a similar IOP when difluprednate was used in less frequency than prednisolone 1%, 24 a future RCT to evaluate the effect of difluprednate vs prednisolone acetate in GDD is still needed.…”

Section: Dovepressmentioning

confidence: 99%

Survey of the American Glaucoma Society Membership on Current Glaucoma Drainage Device Placement and Postoperative Corticosteroid Use

Yonamine¹,

Ton²,

Rose‐Nussbaumer³

et al. 2022

OPTH

Self Cite

View full text Add to dashboard Cite

show abstract

“… 171 In general, older GCs such as DEX, betamethasone, and prednisolone are more likely to induce OHT compared to newer GCs such as loteprednol etabonate, rimexolone, or difluprednate. 172 , 173 Some studies showed that loteprednol etabonate is less likely to induce OHT (≥10 mm Hg from baseline) after short- or long-term use. 174 , 175 Several characteristics of loteprednol etabonate make it an attractive alternative to older GCs: it is more rapidly metabolized after GR activation due to the replacement of a ketone group with an ester group at the carbon 20 position, and it is highly lipophilic with high affinity for the GR which allows for excellent penetration in the ocular tissue.…”

Section: Clinical Science Review Of Gig/giohtmentioning

confidence: 99%

Section: Dovepressmentioning

confidence: 99%

See 1 more Smart Citation

Glucocorticoid-Induced Ocular Hypertension and Glaucoma

Harvey,

Sugali,

Mao

2024

OPTH

View full text Add to dashboard Cite

Glucocorticoid (GC) therapy is indicated in many diseases, including ocular diseases. An important side-effect of GC therapy is GC-induced ocular hypertension (GIOHT), which may cause irreversible blindness known as GC-induced glaucoma (GIG). Here, we reviewed the pathological changes that contribute to GIOHT including in the trabecular meshwork and Schlemm’s canal at cellular and molecular levels. We also discussed the clinical aspects of GIOHT/GIG including disease prevalence, risk factors, the type of GCs, the route of GC administration, and management strategies.

show abstract

Tube Versus Trabeculectomy IRIS Registry Study: 1-Year Secondary Treatment Outcomes

Sun,

McSoley,

Lum

et al. 2023

American Journal of Ophthalmology

View full text Add to dashboard Cite

Surgical Outcomes of Ahmed Glaucoma Valve Implantation with Postoperative Use of Prednisolone Acetate versus Difluprednate

Cited by 7 publications

References 21 publications

Survey of the American Glaucoma Society Membership on Current Glaucoma Drainage Device Placement and Postoperative Corticosteroid Use

Survey of the American Glaucoma Society Membership on Current Glaucoma Drainage Device Placement and Postoperative Corticosteroid Use

Glucocorticoid-Induced Ocular Hypertension and Glaucoma

Tube Versus Trabeculectomy IRIS Registry Study: 1-Year Secondary Treatment Outcomes

Contact Info

Product

Resources

About